Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial

Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial

Abstract Background A two-dose primary regimen of INO-4800 DNA vaccine demonstrated only modest immunogenicity in the previous phase 2 clinical trial. This booster study aimed to evaluate the immunogenicity and safety of a booster dose of INO-4800 in adults previously received two-dose regimen of IN...

Full description

Saved in:
Bibliographic Details
Main Authors: Aihua Yao, Siyue Jia, Xin Cheng, Hongxing Pan, Zhijian Wang, Haitao Yang, Yu Xia, Jianfang Xu, Xuefen Huai, Danjing Leng, Ming Xu, Jiarong Wang, Gan Zhao, Bin Wang, Jingxin Li
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Infectious Diseases
Subjects:
COVID-19
DNA vaccine
Immunogenicity
Safety
Booster immunization
Online Access:https://doi.org/10.1186/s12879-025-11140-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items